85. 特発性間質性肺炎 [臨床試験数:514,薬物数:377(DrugBank:108),標的遺伝子数:97,標的パスウェイ数:204

Searched query = "Idiopathic interstitial pneumonia", "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-002632-24-FR13/11/201820/07/2018to evaluate a triple therapy: plasma exchange, rituximab, intravenous immunoglobulin (IVIg) and corticosteroid administration compared to standard corticosteroid therapy in patients for severe acute exacerbation of idiopathic pulmonaryTherapeutic plasma exchange, rituximab and intravenous immunoglobulins (IVIg) for severe acute exacerbation of idiopathic pulmonary fibrosis admitted in ICU: an open, randomized, controlled trial - EXCHANGE-IFP severe acute exacerbation of idiopathic pulmonary fibrosis;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
40 Human pharmacology (Phase 1): no Therapeut1c exploratory (Phase 2): no Therapeut1c conf1rmatory - (Phase 3): yes Therapeut1c use (Phase 4): noFrance
2NCT03286556September 4, 201812/9/2017Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary FibrosisStudy of Therapeutic Plasma Exchange, Rituximab and Intravenous Immunoglobulin for Acute Exacerbations of Idiopathic Pulmonary Fibrosis (STRIVE-IPF)Idiopathic Pulmonary Fibrosis, Acute Fatal FormDrug: Autoantibody Reductive Therapy;Drug: Treatment as Usual (TAU)University of Alabama at BirminghamNational Heart, Lung, and Blood Institute (NHLBI);Brigham and Women's Hospital;Temple University;University of PittsburghRecruiting40 Years85 YearsAll51Phase 2United States
3NCT03500731April 19, 201830/3/2018Lung and Bone Marrow Transplantation for Lung and Bone Marrow FailureLung Transplant in Tandem With Bone Marrow Transplant for Combined Lung and Bone Marrow FailureIdiopathic Pulmonary Fibrosis;Emphysema or COPDBiological: CD3/CD19 negative hematopoietic stem cells;Drug: Rituximab;Drug: Alemtuzumab;Drug: Fludarabine;Drug: Thiotepa;Drug: G-CSF;Drug: HydroxyureaPaul SzabolcsNULLRecruiting18 Years60 YearsAll8Phase 1/Phase 2United States
4NCT01969409January 201417/10/2013Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary FibrosisAutoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis (ART-IPF)Ambulatory IPFDrug: Rituximab;Drug: PlaceboUniversity of Alabama at BirminghamNational Institutes of Health (NIH)Active, not recruiting50 Years85 YearsAll58Phase 2United States
5NCT01524068September 201227/1/2012A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis ExacerbationsA Multicenter, Open-Label, Phase II Study of Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids in Patients With Acute Idiopathic Pulmonary Fibrosis ExacerbationsIdiopathic Pulmonary FibrosisDrug: Standard Steroid Treatment;Drug: The Standard Steroid Treatment, Plasma Exchange and rituximabUniversity of PittsburghNULLWithdrawn18 Years90 YearsBoth0Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01266317March 201122/12/2010Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis ExacerbationsOpen-Label, Feasibility Study of Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids in Patients With Acute Idiopathic Pulmonary Fibrosis ExacerbationsIPFDrug: Combined Plasma Exchange (PEX), Rituximab, and CorticosteroidsMichael DonahoeNULLCompleted18 Years80 YearsAll9Phase 1/Phase 2United States